Jazz Pharmaceuticals plc (JAZZ)

Market Cap	6.62B
Revenue (ttm)	4.06B
Net Income (ttm)	482.20M
Shares Out	60.51M
EPS (ttm)	7.51
PE Ratio	14.57
Forward PE	13.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	327,043
Open	109.50
Previous Close	109.92
Day's Range	109.12 - 110.04
52-Week Range	95.49 - 148.06
Beta	0.32
Analysts	Strong Buy
Price Target	183.08 (+67.27%)
Earnings Date	Jul 30, 2025

About JAZZ

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enry...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2007
• Employees: 2,800
• Stock Exchange: NASDAQ
• Ticker Symbol: JAZZ
• Website: https://www.jazzpharma.com

Financial Performance

In 2024, Jazz Pharmaceuticals's revenue was $4.07 billion, an increase of 6.12% compared to the previous year's $3.83 billion. Earnings were $560.12 million, an increase of 35.02%.

Analyst Summary

According to 12 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price target is $183.08, which is an increase of 67.27% from the latest price.

Price Target

$183.08

(67.27% upside)

Analyst Consensus: Strong Buy